Abstract
Sildenafil utilization was prospectively evaluated among 153 men with a history of erectile dysfunction (ED)-prescription drug use prior to starting sildenafil and 164 men who were new starters of ED-prescription drugs. Further, some determinants of sildenafil discontinuation were identified. During a median follow-up period of 18 months 45% of all patients discontinued sildenafil treatment, regardless of earlier treatment history. However, patients with a history of drug treatment for ED were nearly eight times as likely to switch or re-start another ED-prescription drug after discontinuing sildenafil compared to previously untreated users. Age >60 y, diabetes medication, nitrate use, and use of incontinence pads (a proxy for disease/surgery in the pelvic region) were associated with an increased likelihood of discontinuing sildenafil. Although the introduction of sildenafil reduced the barrier to seek medical help for erectile problems, sildenafil treatment failure in previously untreated patients results in a high dropout rate from further ED drug treatment of any kind.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Meuleman EJ et al. Erectile dysfunction: prevalence and effect on the quality of life; the Boxmeer study Ned Tijdschr Geneeskd 2001 145: 576–581
Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group New Engl J Med 1998 338: 1397–1404
Souverein PC et al. The Dutch cohort of sildenafil users: baseline characteristics BJU Int 2001 87: 648–653
Leufkens HGM, Urquhart J . Automated record linkage and other approaches to pharmacoepidemiology in The Netherlands In: Strom BL, ed Pharmacoepidemiology 2nd edition John Wiley & Sons: Chichester 1994 pp 231–244
Harrold LR et al. The diffusion of a novel therapy into clinical practice: the case of sildenafil Arch Intern Med 2000 160: 3401–3405
Buvat J, Lemaire A, Ratajezyk J, Attou R . Acceptance, efficacy and preference of sildenafil in 107 patients on long term auto-intracavernosal therapy: a study with follow up at one year (abstract) J Urol 2001 165: 224
El-Galley R et al. Long-term efficacy of sildenafil and tachyphylaxis effect J Urol 2001 166: 927–931
Burnett AL . Oral pharmacotherapy for erectile dysfunction: current perspectives Urology 1999 54: 392–400
Steers WD . Viagra-after one year Urology 1999 54: 12–17
McMahon CG . Erectile dysfunction Med J Aust 2000 173: 492–497
Price D . Sildenafil citrate (Viagra) efficacy in the treatment of erectile dysfunction in patients with common concomitant conditions. Sildenafil Study Group Int J Clin Pract 1999 102: (Suppl) 21–23
Jones JK et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population Br Med J 1995 311: 293–295
Machtens S, Gansslen A, Pohlemann T, Stief CG . Erectile dysfunction in relation to traumatic pelvic injuries or pelvic fractures BJU Int 2001 87: 441–448
Zagaja GP, Mhoon DA, Aikens JE, Brendler CB . Sildenafil in the treatment of erectile dysfunction after radical prostatectomy Urology 2000 56: 631–634
Zippe CD et al. Role of Viagra after radical prostatectomy Urology 2000 55: 241–245
Lue TF . Erectile dysfunction New Engl J Med 2000 342: 1802–1813
Jackson G . Erectile dysfunction and cardiovascular disease Int J Clin Pract 1999 53: 363–368
Webb DJ, Freestone S, Allen MJ, Muirhead GJ . Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist Am J Cardiol 1999 83: 21C–28C
Boer LJ de et al. Diagnostiek en behandeling van erectile dysfunction: een stappenplan Medicom Exel, Bussum 1998 48 pp
McCullough AR, Siegel RL, Shpilsky AB . Intercourse success rates with sildenafil citrate (Abstract) J Urol 2001 165: 170
Acknowledgements
The authors would like to thank all the pharmacies that participated in this study for their kind co-operation. Further, we thank pharmacy students C. van Hooijdonk, T. Mulder, C. Van der Vorst and S. Woudstra for their assistance in data analysis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Souverein, P., Egberts, A., Meuleman, E. et al. Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. Int J Impot Res 14, 259–265 (2002). https://doi.org/10.1038/sj.ijir.3900883
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3900883
Keywords
This article is cited by
-
Men’s beliefs about treatment for erectile dysfunction—what influences treatment use? A systematic review
International Journal of Impotence Research (2021)
-
Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails
Drugs & Aging (2018)
-
Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients
International Journal of Impotence Research (2014)
-
Effects of Ginkgo biloba extracts with mirodenafil on the relaxation of corpus cavernosal smooth muscle and the potassium channel activity of corporal smooth muscle cells
Asian Journal of Andrology (2011)
-
Motivations for seeking treatment for ED: the woman's perspective
International Journal of Impotence Research (2010)